title: Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study.
abstract: BACKGROUND
  VKORC1 and CYP2C9 are important contributors to warfarin dose variability, but explain less variability for individuals of African descent than for those of European or Asian descent. We aimed to identify additional variants contributing to warfarin dose requirements in African Americans.
  
  
  METHODS
  We did a genome-wide association study of discovery and replication cohorts. Samples from African-American adults (aged ≥18 years) who were taking a stable maintenance dose of warfarin were obtained at International Warfarin Pharmacogenetics Consortium (IWPC) sites and the University of Alabama at Birmingham (Birmingham, AL, USA). Patients enrolled at IWPC sites but who were not used for discovery made up the independent replication cohort. All participants were genotyped. We did a stepwise conditional analysis, conditioning first for VKORC1 -1639G→A, followed by the composite genotype of CYP2C9*2 and CYP2C9*3. We prespecified a genome-wide significance threshold of p<5×10(-8) in the discovery cohort and p<0·0038 in the replication cohort.
  
  
  RESULTS
  The discovery cohort contained 533 participants and the replication cohort 432 participants. After the prespecified conditioning in the discovery cohort, we identified an association between a novel single nucleotide polymorphism in the CYP2C cluster on chromosome 10 (rs12777823) and warfarin dose requirement that reached genome-wide significance (p=1·51×10(-8)). This association was confirmed in the replication cohort (p=5·04×10(-5)); analysis of the two cohorts together produced a p value of 4·5×10(-12). Individuals heterozygous for the rs12777823 A allele need a dose reduction of 6·92 mg/week and those homozygous 9·34 mg/week. Regression analysis showed that the inclusion of rs12777823 significantly improves warfarin dose variability explained by the IWPC dosing algorithm (21% relative improvement).
  
  
  CONCLUSIONS
  A novel CYP2C single nucleotide polymorphism exerts a clinically relevant effect on warfarin dose in African Americans, independent of CYP2C9*2 and CYP2C9*3. Incorporation of this variant into pharmacogenetic dosing algorithms could improve warfarin dose prediction in this population.
  
  
  BACKGROUND
  National Institutes of Health, American Heart Association, Howard Hughes Medical Institute, Wisconsin Network for Health Research, and the Wellcome Trust.
authors.affiliation: Section of Genetic Medicine, Department of Medicine, University of Chicago, IL, USA.
authors.forename: Minoli A
authors.initials: MA
authors.lastname: Perera
authors.forename: Larisa H
authors.initials: LH
authors.lastname: Cavallari
authors.forename: Nita A
authors.initials: NA
authors.lastname: Limdi
authors.forename: Eric R
authors.initials: ER
authors.lastname: Gamazon
authors.forename: Anuar
authors.initials: A
authors.lastname: Konkashbaev
authors.forename: Roxana
authors.initials: R
authors.lastname: Daneshjou
authors.forename: Anna
authors.initials: A
authors.lastname: Pluzhnikov
authors.forename: Dana C
authors.initials: DC
authors.lastname: Crawford
authors.forename: Jelai
authors.initials: J
authors.lastname: Wang
authors.forename: Nianjun
authors.initials: N
authors.lastname: Liu
authors.forename: Nicholas
authors.initials: N
authors.lastname: Tatonetti
authors.forename: Stephane
authors.initials: S
authors.lastname: Bourgeois
authors.forename: Harumi
authors.initials: H
authors.lastname: Takahashi
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Bradford
authors.forename: Benjamin M
authors.initials: BM
authors.lastname: Burkley
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Desnick
authors.forename: Jonathan L
authors.initials: JL
authors.lastname: Halperin
authors.forename: Sherief I
authors.initials: SI
authors.lastname: Khalifa
authors.forename: Taimour Y
authors.initials: TY
authors.lastname: Langaee
authors.forename: Steven A
authors.initials: SA
authors.lastname: Lubitz
authors.forename: Edith A
authors.initials: EA
authors.lastname: Nutescu
authors.forename: Matthew
authors.initials: M
authors.lastname: Oetjens
authors.forename: Mohamed H
authors.initials: MH
authors.lastname: Shahin
authors.forename: Shitalben R
authors.initials: SR
authors.lastname: Patel
authors.forename: Hersh
authors.initials: H
authors.lastname: Sagreiya
authors.forename: Matthew
authors.initials: M
authors.lastname: Tector
authors.forename: Karen E
authors.initials: KE
authors.lastname: Weck
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Rieder
authors.forename: Stuart A
authors.initials: SA
authors.lastname: Scott
authors.forename: Alan H B
authors.initials: AH
authors.lastname: Wu
authors.forename: James K
authors.initials: JK
authors.lastname: Burmester
authors.forename: Mia
authors.initials: M
authors.lastname: Wadelius
authors.forename: Panos
authors.initials: P
authors.lastname: Deloukas
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Wagner
authors.forename: Taisei
authors.initials: T
authors.lastname: Mushiroda
authors.forename: Michiaki
authors.initials: M
authors.lastname: Kubo
authors.forename: Dan M
authors.initials: DM
authors.lastname: Roden
authors.forename: Nancy J
authors.initials: NJ
authors.lastname: Cox
authors.forename: Russ B
authors.initials: RB
authors.lastname: Altman
authors.forename: Teri E
authors.initials: TE
authors.lastname: Klein
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Nakamura
authors.forename: Julie A
authors.initials: JA
authors.lastname: Johnson
mesh_terms: D001741:Black or African American / Q000235:genetics*; D000483:Alleles; D000925:Anticoagulants / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D065729:Cytochrome P-450 CYP2C9; D005260:Female; D055106:Genome-Wide Association Study; D005838:Genotype; D006801:Humans; D008297:Male; D006899:Mixed Function Oxygenases / Q000235:genetics; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D064417:Vitamin K Epoxide Reductases; D014859:Warfarin / Q000008:administration & dosage* / Q000493:pharmacokinetics
chemical_list: D000925:Anticoagulants; D014859:Warfarin; D006899:Mixed Function Oxygenases; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; C578523:VKORC1 protein, human; D064417:Vitamin K Epoxide Reductases